<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004585.pub2" GROUP_ID="STROKE" ID="402202052009121698" MERGED_FROM="" MODIFIED="2008-08-25 10:57:54 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-08-25 10:57:54 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>EMG biofeedback for the recovery of motor function after stroke</TITLE>
<CONTACT MODIFIED="2008-08-25 10:57:54 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16560" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Henry</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Woodford</LAST_NAME><POSITION>Consultant Physician</POSITION><EMAIL_1>henry.woodford@ncumbria-acute.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Elderly Medicine</DEPARTMENT><ORGANISATION>Cumberland Infirmary</ORGANISATION><ADDRESS_1>Newtown Road</ADDRESS_1><CITY>Carlisle</CITY><ZIP>CA2 7HY</ZIP><REGION>Cumbria</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1228 523444</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-08-25 10:57:54 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16560" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Henry</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Woodford</LAST_NAME><POSITION>Consultant Physician</POSITION><EMAIL_1>henry.woodford@ncumbria-acute.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Elderly Medicine</DEPARTMENT><ORGANISATION>Cumberland Infirmary</ORGANISATION><ADDRESS_1>Newtown Road</ADDRESS_1><CITY>Carlisle</CITY><ZIP>CA2 7HY</ZIP><REGION>Cumbria</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1228 523444</PHONE_1></ADDRESS></PERSON><PERSON ID="16528" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christopher</FIRST_NAME><MIDDLE_INITIALS>IM</MIDDLE_INITIALS><LAST_NAME>Price</LAST_NAME><POSITION>Clinical Senior Lecturer/Consultant Physician</POSITION><EMAIL_1>christopher.price@northumbria-healthcare.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Elderly Services</DEPARTMENT><ORGANISATION>Northumbria Healthcare NHS Trust</ORGANISATION><ADDRESS_1>Wansbeck General Hospital</ADDRESS_1><ADDRESS_2>Woodhorn Lane</ADDRESS_2><CITY>Ashington</CITY><ZIP>NE63 9JJ</ZIP><REGION>Northumberland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1670 521212</PHONE_1><FAX_1>+44 1670 529183</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-19 12:26:37 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="14" MONTH="9" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="3" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="19" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-08-19 12:27:04 +0100" MODIFIED_BY="Hazel Fraser"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-19 12:35:08 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-08-19 12:28:16 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-08-19 12:28:01 +0100" MODIFIED_BY="Hazel Fraser">EMG biofeedback for the recovery of motor function after stroke</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-19 12:28:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>Electromyographic biofeedback (techniques using visual or sound signals to monitor muscle activity) has an uncertain impact on recovery after stroke. Electromyographic biofeedback (EMG-BFB) uses electrodes placed on a patient's muscles to generate a feedback signal (in vision or sound) in response to muscle activation. It is believed that this may allow patients to learn a more effective way of using their disabled limb. Amongst the 13 studies identified, there was a small amount of evidence to suggest that EMG-BFB had a beneficial effect when used with standard physiotherapy techniques. However EMG-BFB cannot currently be recommended as an effective routine treatment because other studies found no effect, and the positive trials were small.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Electromyographic biofeedback (EMG-BFB) is a technique that is believed to have additional benefit when used with standard physiotherapy for the recovery of motor function in stroke patients. However, evidence from individual trials and previous systematic reviews has been inconclusive.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of EMG-BFB for motor function recovery following stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Stroke Group Trials Register (last searched 30 March 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 4, 2005), MEDLINE (1966 to November 2005), EMBASE (1980 to November 2005), CINAHL (1983 to November 2005), PsycINFO (1974 to November 2005) and First Search (1966 to November 2005). We scanned reference lists for relevant articles and contacted equipment manufacturers and distributors. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised and quasi-randomised studies comparing EMG-BFB with control for motor function recovery in stroke patients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors independently assessed trial quality and extracted data. Where possible we contacted study authors for further information. Any reported adverse effects were noted.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Thirteen trials involving 269 people were included. All trials compared EMG-BFB plus standard physiotherapy to standard physiotherapy either alone or with sham EMG-BFB. Only one study used a motor strength assessment scale for evaluation of patients, which indicated benefit from EMG-BFB (WMD 1.09, 95% CI 0.48 to 1.70). EMG-BFB did not have a significant benefit in improving range of motion (ROM) through the ankle (SMD 0.05, 95% CI -0.36 to 0.46), knee or wrist joints. However, one trial suggested a benefit in ROM at the shoulder (SMD 0.88, 95% CI 0.07 to 1.70). Change in stride length or gait speed was not improved by EMG-BFB. Two studies used different assessment scores to quantify gait quality. One of these suggested a beneficial effect of EMG-BFB (SMD 0.90, 95% CI 0.01 to 1.78). Most of the studies examining functional outcomes used different assessment scales, which made meta-analysis impossible. Two studies that used the same scale did show a beneficial effect (SMD 0.69, 95% CI 0.15 to 1.23).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Despite evidence from a small number of individual studies to suggest that EMG-BFB plus standard physiotherapy produces improvements in motor power, functional recovery and gait quality when compared to standard physiotherapy alone, combination of all the identified studies did not find a treatment benefit. Overall the results are limited because the trials were small, generally poorly designed and utilised varying outcome measures. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-19 12:35:08 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND>
<P>Stroke is a major cause of disability. There are an estimated nine million stroke survivors worldwide per year and this figure is predicted to rise 30% between the years 1983 and 2023 (<LINK REF="REF-Wolfe-2000" TYPE="REFERENCE">Wolfe 2000</LINK>). Around one third of those alive at six months following a stroke are functionally dependent on others (<LINK REF="REF-Warlow-1998" TYPE="REFERENCE">Warlow 1998</LINK>). To date, the major management of most strokes remains rehabilitation and secondary prevention. Any technique that could enable a more rapid or complete functional recovery would have major benefits both in terms of patients' well-being and health economics.</P>
<P>Biofeedback (BFB) has been used in rehabilitation for over 40 years (<LINK REF="REF-De-Weerdt-1985" TYPE="REFERENCE">De Weerdt 1985</LINK>). The technique tries to transduce a physiological electrical response, which would normally be subliminal, into an auditory or visual stimulus to the patient. In terms of motor function recovery this is normally in the form of an electromyogram (EMG). This records a difference in potential along the length of a muscle using electrodes over the skin surface. After amplification, the signal is displayed in a simplified format to the patient, for example, by hearing a change in auditory tone or by seeing a response on an oscilloscope display (<LINK REF="REF-De-Weerdt-1986a" TYPE="REFERENCE">De Weerdt 1986a</LINK>). </P>
<P>The theory is that, following a stroke, the normal regulation of muscle tone is disrupted by neuronal damage, which leads to both inappropriate decreases and increases (spasticity) in muscular activity. It is proposed that the patient may have some unaffected pathways preserved but that these may not be initially obvious (<LINK REF="REF-Glanz-1997" TYPE="REFERENCE">Glanz 1997</LINK>). By using electromyogram biofeedback (EMG-BFB) it may be possible for individuals to learn how to use these preserved pathways. They may then be able to control muscular activity in order to recover motor function following a stroke.</P>
<P>Despite its continuing use in rehabilitation, there remains doubt over the efficacy of this technique. EMG-BFB is referenced within the Royal College of Physicians' guidelines on stroke (<LINK REF="REF-RCPstroke-2004" TYPE="REFERENCE">RCPstroke 2004</LINK>), concluding that there is currently no evidence of advantage over traditional therapy. A previous recommendation in favour of its use has been withdrawn. A number of review articles have not found clear evidence of benefit (<LINK REF="REF-De-Weerdt-1986b" TYPE="REFERENCE">De Weerdt 1986b</LINK>; <LINK REF="REF-Glanz-1995" TYPE="REFERENCE">Glanz 1995</LINK>; <LINK REF="REF-Glanz-1997" TYPE="REFERENCE">Glanz 1997</LINK>; <LINK REF="REF-Moreland-1998" TYPE="REFERENCE">Moreland 1998</LINK>; <LINK REF="REF-Schleenbaker-1993" TYPE="REFERENCE">Schleenbaker 1993</LINK>). <BR/> </P>
</BACKGROUND>
<OBJECTIVES>
<P>The specific objective of this review was to determine the efficacy of any form of EMG-BFB used after a stroke in order to aid motor function recovery.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-19 12:30:21 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-08-19 12:28:39 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES>
<P>We considered all randomised controlled trials (RCTs) and quasi-randomised controlled trials comparing EMG-BFB with no EMG-BFB or sham EMG-BFB. We contacted individual trialists, where necessary, in cases where treatment allocation was uncertain. We noted blinding of outcome assessment, but did not use this to exclude trials. We did not consider it essential that the control group received a sham treatment, but we noted any placebo.<BR/> </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We considered trials that included patients of any age or gender with a clinical diagnosis of stroke, with or without a computerised tomography (CT) scan. We did not use previous stroke as a basis for exclusion. We did not identify any otherwise suitable trials that included a mixed group of subjects with other causes for their neurological injury. No predetermined time limit was set for how soon after stroke the EMG-BFB technique was performed.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We used the study authors' definitions of EMG-BFB. Techniques were expected to involve electrodes being placed on the skin surface above the muscle group being tested, with the electrical activity displayed to the patient in either a visual or auditory format. We recorded all variations in the muscle groups used, forms of biofeedback undertaken and duration of therapy to the recipient. We excluded studies which had EMG-BFB as only one part of a multiple intervention package (e.g. EMG-BFB plus electrical stimulation versus control) unless the results of the studies recorded the outcome data separately for the individual interventions.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-19 12:28:39 +0100" MODIFIED_BY="Hazel Fraser">
<P>We extracted six types of outcome data from identified trials to allow an intention-to-treat analysis. The primary outcome measure was the change in muscle power relative to baseline in the intervention and control groups. The five secondary outcomes were:<BR/>
</P>
<UL>
<LI>the change in range of motion through a specified joint (degrees) relative to baseline in intervention and control groups;</LI>
<LI>improvement in gait, measured by changes in stride length (centimetres) or speed (seconds) and changes in needs for ambulation aids relative to baseline in intervention and control groups;</LI>
<LI>the change in function ability relative to baseline in intervention and control groups;</LI>
<LI>the change in electromyographic activity relative to the baseline recording;</LI>
<LI>the proportion of subjects with muscle weakness due to stroke in treatment and control groups.</LI>
</UL>
<P>We did not include studies which only reported EMG activity as an outcome. EMG potentials alone have no direct functional significance, there is a wide variation in calibration, and as different authors average their values, the absolute readings are not directly comparable.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-19 12:30:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator on 30 March 2006. In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 4, 2005), MEDLINE (January 1966 to November 2005), EMBASE (January 1980 to November 2005), First Search (January 1966 to November 2005), CINAHL (January 1983 to November 2005) and PsycINFO (January 1974 to November 2005) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<P>In an attempt to identify further published, unpublished and ongoing trials, we scanned reference lists of relevant articles and contacted equipment manufacturers and distributors (Thought Technology Limited and Bio-Medical Instruments). Articles published in languages other than English were translated.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two independent review authors with a background in stroke rehabilitation medicine screened the titles and abstracts of articles identified by the electronic searches. They decided which trials met the inclusion criteria, and judged their methodological quality. Allocation concealment before randomisation was scored using The Cochrane Collaboration's grading system: A - adequate; B - unclear; C - inadequate; or D - not used. We used checklists to independently record details of the randomisation method, study population, EMG methods employed, length of follow up, and outcome measures. We carefully noted the proportions of participants that completed the intervention period, and reasons why they left the study prematurely. Analysis was by intention to treat. Extracted data were checked for agreement between review authors. We attempted to contact trialists to request missing data. </P>
<P>We calculated a weighted treatment effect for each of the outcome measures. Outcomes were combined using the weighted mean difference (WMD) for identical measures, and standardised mean difference (SMD) for different measures. Where there was obvious variation between the WMD or SMD of individual studies (P value &lt; 0.1), a random-effects model was applied.</P>
<P>Motor function after stroke has been recorded by a variety of clinical rating scales such as the Medical Research Council scale. It has also been measured directly by force transduction devices. A number of functional assessment tools have been utilised, such as the upper extremity functional test (UEFT), the action research arm test (ARA), and the Nottingham 10 point activities of daily living (ADL) scale. It is not clear which method is best. Therefore, the results should be interpreted with some caution, and the reliability of such measures will be left to the judgement of readers of this review. We recorded length of follow up, and noted whether assessors were blinded to treatment allocation. We reported attrition rates if known.</P>
<P>We planned sensitivity analyses a priori for studies that had the following characteristics:<BR/>
</P>
<UL>
<LI>true randomised versus quasi-randomised;</LI>
<LI>blinded versus unblinded treatment;</LI>
<LI>blinded versus unblinded outcome measurement;</LI>
<LI>placebo (sham treatment) versus none;</LI>
<LI>time after stroke before use of EMG biofeedback technique.</LI>
</UL>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-19 12:35:08 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION>
<P>The search strategy outlined above identified 23 RCTs utilising EMG-BFB in the rehabilitation of stroke patients. Ten of these were excluded from the analysis for a combination of the following reasons: insufficient raw data, despite attempts to contact the authors (<LINK REF="STD-Basmajian-1982" TYPE="STUDY">Basmajian 1982</LINK>; <LINK REF="STD-Ince-1987" TYPE="STUDY">Ince 1987</LINK>; <LINK REF="STD-Mandel-1990" TYPE="STUDY">Mandel 1990</LINK>; <LINK REF="STD-Olney-1997" TYPE="STUDY">Olney 1997</LINK>; <LINK REF="STD-Prevo-1982" TYPE="STUDY">Prevo 1982</LINK>; <LINK REF="STD-Shahani-1977" TYPE="STUDY">Shahani 1977</LINK>; <LINK REF="STD-Taskiran-1993" TYPE="STUDY">Taskiran 1993</LINK>; <LINK REF="STD-Wolf-1994" TYPE="STUDY">Wolf 1994</LINK>); the use of a cross-over design without the capacity to extract data after the first intervention period (<LINK REF="STD-Chen-1980" TYPE="STUDY">Chen 1980</LINK>); and inability to obtain the original article (<LINK REF="STD-Ince-1991" TYPE="STUDY">Ince 1991</LINK>). Thirteen studies, involving 269 patients (mean number per study = 21, range 9 to 40), were included in the analysis (<LINK REF="STD-Armagan-2003" TYPE="STUDY">Armagan 2003</LINK>; <LINK REF="STD-Basmajian-1987" TYPE="STUDY">Basmajian 1987</LINK>; <LINK REF="STD-Binder-1981" TYPE="STUDY">Binder 1981</LINK>; <LINK REF="STD-Bradley-1998" TYPE="STUDY">Bradley 1998</LINK>; <LINK REF="STD-Burnside-1982" TYPE="STUDY">Burnside 1982</LINK>; <LINK REF="STD-Cozean-1988" TYPE="STUDY">Cozean 1988</LINK>; <LINK REF="STD-Crow-1989" TYPE="STUDY">Crow 1989</LINK>; <LINK REF="STD-Inglis-1984" TYPE="STUDY">Inglis 1984</LINK>; <LINK REF="STD-Intiso-1994" TYPE="STUDY">Intiso 1994</LINK>; <LINK REF="STD-Lee-1985" TYPE="STUDY">Lee 1985</LINK>; <LINK REF="STD-Mroczek-1978" TYPE="STUDY">Mroczek 1978</LINK>; <LINK REF="STD-Mulder-1986" TYPE="STUDY">Mulder 1986</LINK>; <LINK REF="STD-Smith-1979" TYPE="STUDY">Smith 1979</LINK>).</P>
<P>From the studies that stated values, the mean age of subjects was 62 years (range 52 to 70), and the mean percentage of males was 62 (range 45% to 81%). It is worth noting that there was a very wide variation between studies for the time from the stroke to randomisation (mean time 255 days; range 35 to 1140 days). The duration of studies ranged form four to 16 weeks, with a six-week intervention period being most common. All participants had a residual weakness of either the upper or lower limb. Insufficient cognitive capacity to participate in the program, including receptive dysphasia, was a common reason for patient exclusion. There was a wide variation in the outcome measures used. None of the included studies used EMG potentials alone as an outcome assessment. </P>
<P>The studies had different time intervals between the intervention period and later outcome measures, so only the readings taken at the end of the intervention period were included.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-19 12:35:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>Details of the included studies are shown in the 'Characteristics of included studies' table. Reliable randomisation was described in only one study (<LINK REF="STD-Armagan-2003" TYPE="STUDY">Armagan 2003</LINK>), which was by numbered envelopes. Four studies used quasi-randomised methods (<LINK REF="STD-Basmajian-1987" TYPE="STUDY">Basmajian 1987</LINK>; <LINK REF="STD-Burnside-1982" TYPE="STUDY">Burnside 1982</LINK>; <LINK REF="STD-Crow-1989" TYPE="STUDY">Crow 1989</LINK>; <LINK REF="STD-Mroczek-1978" TYPE="STUDY">Mroczek 1978</LINK>). A sham form of EMG-BFB (the machine attached but either switched off or not visible to the patient) was used in two studies (<LINK REF="STD-Armagan-2003" TYPE="STUDY">Armagan 2003</LINK>; <LINK REF="STD-Burnside-1982" TYPE="STUDY">Burnside 1982</LINK>). In one study randomisation was not mentioned at all (<LINK REF="STD-Intiso-1994" TYPE="STUDY">Intiso 1994</LINK>). Given the small number of suitable studies identified, this has still been included as the presentation of results suggests at least quasi-randomisation.</P>
<P>In all studies that specified within their methods, assessment was performed by an individual blinded to the patients' treatments. No adverse events relating to interventions were reported in any study. Two studies reported sub-optimal completion rates. In one, two patients in the control group died (<LINK REF="STD-Bradley-1998" TYPE="STUDY">Bradley 1998</LINK>), in another two patients in the control group were withdrawn due to a further stroke and a fractured neck of femur (<LINK REF="STD-Intiso-1994" TYPE="STUDY">Intiso 1994</LINK>). The data from these four patients were not included in the subsequent analyses.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-19 12:35:08 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.1: Change in motor strength</HEADING>
<P>Although initially identified as the primary outcome prior to the search, only one study used a motor strength assessment (the Medical Research Council scale). Of course, this makes meta-analysis impossible. However, the result of this study was positive for a benefit of EMG-BFB (weighted mean difference (WMD) 1.09, 95% confidence interval (CI) 0.48 to 1.70).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.2: Change in range of motion</HEADING>
<P>Eight trials used the range of motion (ROM) through a joint as an outcome measure: five at the ankle, and one each for the shoulder, wrist, and knee. A combination of results from studies assessing ankle ROM, including a total of 91 patients, did not demonstrate a significant effect of EMG-BFB (standardised mean difference (SMD) 0.05, 95% CI -0.36 to 0.46), nor did individual trial results for the knee or wrist. However, the only trial assessing ROM at the shoulder did suggest a beneficial effect (SMD 0.88, 95% CI 0.07 to 1.70).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.3: Change in stride length</HEADING>
<P>Two studies calculated the number of steps taken to walk a specified distance (6 or 10 metres). Two studies measured stride length before and after the intervention period. None of the results alone reached significance. The differing outcome measures made meta-analysis impossible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.4: Change in gait speed</HEADING>
<P>Three studies measured the time taken to walk a specified distance (6, 10 or 50 metres). A further study measured gait cycle time, and another measured walking velocity. The combined result of the three studies assessing time over a specified distance did not show a significant effect (SMD 0.13, 95% CI -0.55 to 0.80). None of the other studies demonstrate a significant benefit with EMG-BFB.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.5: Changes in functional ability</HEADING>
<P>Six studies incorporated functional outcome measures into the patient assessments. Two of these studies used more than one functional measure. For the purposes of this review, only one measure was included from each study. Unfortunately only two of the studies used the same assessment scales as each other. A combination of the results for change in Brunnstrom Stages of Recovery scores did show a significant effect (SMD 0.69, 95% CI 0.15 to 1.23). Individual trial results did not demonstrate a significant effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.6: Change in gait quality score</HEADING>
<P>Two studies used different assessment scores to quantify gait quality. One of these suggested a small positive effect of EMG-BFB compared to controls (SMD 0.90, 95% CI 0.01 to 1.78).</P>
<P>Sensitivity analyses were only possible for comparison of change in range of ankle motion between groups that had a sham intervention versus no placebo, and between those studies with a time interval of less than or more than six months after onset of stroke. There was only one study that used a sham intervention, and that showed no significant difference compared to no placebo. The comparison between groups less than or more than six months from stroke onset did not reveal any significant difference in outcomes.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Despite several decades of EMG-BFB use in stroke rehabilitation, a randomised trial recruiting over 40 patients has not been performed. The small sample sizes make it possible for a positive treatment effect to have been missed, even after combination of studies. Statistical combination of studies is also hampered by the different outcome measures used in each. Some studies could not be included due to the inadequate publication of raw data in original articles, the inability to contact authors, and the loss of data (mainly due to the long time periods that have passed since the studies were done).</P>
<P>Overall, the data available do not demonstrate an effect of EMG-BFB in the restoration of ROM through a specified joint, functional ability scales, or in improvements in stride length or gait speed following a disabling stroke. However, there is some evidence from individual trials of improvements in gait quality assessments, ROM at the shoulder and restoration of motor power. In addition, when combined, two trials suggested a benefit in a functional recovery score. It would seem reasonable to expect that improvements in motor power would lead to an increase in ROM at a joint, and that improved gait quality should result in improved gait speed and stride length. The discrepancy between the findings is physiologically inconsistent.</P>
<P>The reasons for study outcome variance may be related to the small numbers of participants and short time periods used in the studies. Also, the trials vary in the time from stroke to randomisation. However, the trials showing benefit in motor power and gait quality scores had the longest mean time interval from stroke (<LINK REF="STD-Burnside-1982" TYPE="STUDY">Burnside 1982</LINK>; <LINK REF="STD-Smith-1979" TYPE="STUDY">Smith 1979</LINK>), yet the trials demonstrating benefit in functional assessment scales included those with the shortest time interval (<LINK REF="STD-Bradley-1998" TYPE="STUDY">Bradley 1998</LINK>; <LINK REF="STD-Crow-1989" TYPE="STUDY">Crow 1989</LINK>). This analysis is not able to assess whether the observed benefits are maintained or tend to reduce over time.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>When all the available data are combined, EMG-BFB does not appear to have any positive benefit for recovery after stroke. It cannot be recommended as a routine treatment. A small amount of evidence from individual studies suggests that using EMG-BFB in combination with standard physiotherapy regimes may result in improvements in motor power, ROM at the shoulder, functional recovery and gait quality beyond those of standard physiotherapy alone. As there were no reported adverse effects, it would seem reasonable for EMG-BFB to be considered as a cautious treatment approach for individual patients whose circumstances match the inclusion criteria of the studies included in this review. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is need for a randomised clinical trial with adequate power, using standardised assessment scales and robust adverse event reporting, to assess the effectiveness of EMG-BFB.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Initial literature search and wording of the background by Henry Woodford. Guidance and feedback comments provided by Christopher Price. Study articles reviewed by both authors.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Armagan-2003" NAME="Armagan 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armagan O, Tascioglu F, Oner C</AU>
<TI>Electromyographic biofeedback in the treatment of the hemiplegic hand: a placebo-controlled study</TI>
<SO>American Journal of Physical and Medical Rehabilitation</SO>
<YR>2003</YR>
<VL>82</VL>
<NO>11</NO>
<PG>856-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basmajian-1987" NAME="Basmajian 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basmajian JV, Gowland CA, Finlayson AJ, Hall AL, Swanson LR, Stratford PW, et al</AU>
<TI>Stroke treatment: comparison of integrated behavioural-physical therapy vs traditional physical therapy programs</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1987</YR>
<VL>68</VL>
<PG>267-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Binder-1981" NAME="Binder 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Binder S, Moll CB, Wolf SL</AU>
<TI>Evaluation of electromyographic biofeedback as an adjunct to therapeutic exercise in treating the lower extremities of hemiplegic patients</TI>
<SO>Physical Therapy</SO>
<YR>1981</YR>
<VL>61</VL>
<NO>6</NO>
<PG>886-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradley-1998" NAME="Bradley 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradley L, Hart BB, Mandana S, Flowers K, Riches M, Sanderson P</AU>
<TI>Electromyographic biofeedback for gait training after stroke</TI>
<SO>Clinical Rehabilitation</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>11-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burnside-1982" NAME="Burnside 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burnside IG, Tobias HS, Bursill D</AU>
<TI>Electromyographic feedback in the remobilization of stroke patients: a controlled trial</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1982</YR>
<VL>63</VL>
<PG>217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cozean-1988" NAME="Cozean 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cozean CD, Pease WS, Hubbell SL</AU>
<TI>Biofeedback and functional electrical stimulation in stroke rehabilitation</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1988</YR>
<VL>69</VL>
<PG>401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crow-1989" NAME="Crow 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crow JL, Lincoln NB, Nouri FM, de Weerdt W</AU>
<TI>The effectiveness of EMG biofeedback in the treatment of arm function after stroke</TI>
<SO>International Disability Studies</SO>
<YR>1989</YR>
<VL>11</VL>
<NO>4</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inglis-1984" NAME="Inglis 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inglis J, Donald MW, Monga TN, Sproule M, Young MJ</AU>
<TI>Electromyographic biofeedback and physical therapy of the hemiplegic upper limb</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1984</YR>
<VL>65</VL>
<PG>755-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Intiso-1994" NAME="Intiso 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Intiso D, Santilli V, Grasso MG, Rossi R, Caruso I</AU>
<TI>Rehabilitation of walking with electromyographic biofeedback in foot-drop after stroke</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1189-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1985" NAME="Lee 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee SJ, Ahn YP</AU>
<TI>Clinical effect of electromyographic biofeedback treatment in hemiplegic patients</TI>
<SO>Journal of the Catholic Medical College</SO>
<YR>1985</YR>
<VL>38</VL>
<NO>1</NO>
<PG>387-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mroczek-1978" NAME="Mroczek 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mroczek N, Halpern D, McHugh R</AU>
<TI>Electromyographic feedback and physical therapy for neuromuscular retraining in hemiplegia</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1978</YR>
<VL>59</VL>
<PG>258-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulder-1986" NAME="Mulder 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulder T, Hulstijn W, van der Meer J</AU>
<TI>EMG feedback and the restoration of motor control: a controlled group study of 12 hemiparetic patients</TI>
<SO>American Journal of Physical Medicine</SO>
<YR>1986</YR>
<VL>65</VL>
<NO>4</NO>
<PG>173-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1979" NAME="Smith 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith K</AU>
<TI>Biofeedback in strokes</TI>
<SO>Australian Journal of Physiotherapy</SO>
<YR>1979</YR>
<VL>25</VL>
<NO>4</NO>
<PG>155-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Basmajian-1982" NAME="Basmajian 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basmajian JV, Gowland CA, Brandstater ME, Swanson LR, Trotter JE</AU>
<TI>EMG feedback treatment of upper limb hemiplegic stroke patients: a pilot study</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1982</YR>
<VL>63</VL>
<PG>613-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1980" NAME="Chen 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen H, Chu M, Sung M</AU>
<TI>Electromyographic biofeedback treatment in hemiplegia</TI>
<SO>Chinese Medical Journal</SO>
<YR>1980</YR>
<VL>27</VL>
<NO>3</NO>
<PG>557-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ince-1987" NAME="Ince 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ince LP, Zaretsky HH, Lee MHM, Kerman-Lerner P, Adler J</AU>
<TI>Integrating EMG biofeedback treatment of the impaired upper extremity into the rehabilitation programs of stroke patients</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1987</YR>
<VL>68</VL>
<PG>645</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ince-1991" NAME="Ince 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ince LP, Jette CB, Zaretsky HH, Lee MH</AU>
<TI>Biofeedback: an integrated rehabilitation modality for restoration of upper extremity function in stroke patients</TI>
<SO>Medical Psychotherapy</SO>
<YR>1991</YR>
<VL>4</VL>
<PG>95-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandel-1990" NAME="Mandel 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandel AR, Nymark JR, Balmer SJ, Grinnell DM, O'Riain MD</AU>
<TI>Electromyographic versus rhythmic positional biofeedback in computerized gait retraining with stroke patients</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1990</YR>
<VL>71</VL>
<PG>649-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olney-1997" NAME="Olney 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olney S, Nymark J, Zee B, Martin C, Mcnamara P</AU>
<TI>Effects of computer assisted gait retraining (BioTRAC) in early stroke: a randomised clinical trial</TI>
<SO>Journal of Stroke and Cerebrovascular Disorders</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>457</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prevo-1982" NAME="Prevo 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prevo AJH, Visser SL, Vogelaar TW</AU>
<TI>Effect of EMG feedback on paretic muscles and abnormal co-contraction in the hemiplegic arm, compared with conventional physiotherapy</TI>
<SO>Scandinavian Journal of Rehabilitation Medicine</SO>
<YR>1982</YR>
<VL>14</VL>
<PG>121-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shahani-1977" NAME="Shahani 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shahani BT, Connors L, Mohr JP</AU>
<TI>Electromyographic audiovisual feedback training effect on the motor performance in patients with lesions of the central nervous system</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1977</YR>
<VL>58</VL>
<PG>519</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taskiran-1993" NAME="Taskiran 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tasikran FH</AU>
<TI>The effect of EMG biofeedback for the stabilization of the ankle in the hemiplegic patients</TI>
<TO>Hemiplejik hastalarda ayak bilegi stabilizasyonunun saglanmasinda EMG biofeedback in etkinligi</TO>
<SO>Istanbul Tip Fakultesi Mecmuaya</SO>
<YR>1993</YR>
<VL>56</VL>
<NO>4</NO>
<PG>49-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-1994" NAME="Wolf 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf SL, Catlin PA, Blanton S, Edelman J, Lehrer N, Schroeder D</AU>
<TI>Overcoming limitations in elbow movement in the presence of antagonist hyperactivity</TI>
<SO>Physical Therapy</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>9</NO>
<PG>826-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-De-Weerdt-1985" NAME="De Weerdt 1985" TYPE="JOURNAL_ARTICLE">
<AU>De Weerdt WJG, Harrison MA</AU>
<TI>The use of biofeedback in physiotherapy</TI>
<SO>Physiotherapy</SO>
<YR>1985</YR>
<VL>71</VL>
<NO>1</NO>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Weerdt-1986a" NAME="De Weerdt 1986a" TYPE="JOURNAL_ARTICLE">
<AU>De Weerdt WJG, Harrison MA</AU>
<TI>Electromyographic biofeedback for stroke patients: some practical considerations</TI>
<SO>Physiotherapy</SO>
<YR>1986</YR>
<VL>72</VL>
<NO>2</NO>
<PG>106-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Weerdt-1986b" NAME="De Weerdt 1986b" TYPE="JOURNAL_ARTICLE">
<AU>De Weerdt WJG, Harrison MA</AU>
<TI>The efficacy of electromyographic feedback for stroke patients: a critical review of the main literature</TI>
<SO>Physiotherapy</SO>
<YR>1986</YR>
<VL>72</VL>
<NO>2</NO>
<PG>108-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanz-1995" NAME="Glanz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Glanz M, Klawansky S, Stason W, Berkey C, Shah N, Phan H, et al</AU>
<TI>Biofeedback therapy in poststroke rehabilitation: a meta-analysis of the randomised controlled trials</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1995</YR>
<VL>76</VL>
<PG>508-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanz-1997" NAME="Glanz 1997" TYPE="JOURNAL_ARTICLE">
<AU>Glanz M, Klawansky S, Chalmers T</AU>
<TI>Biofeedback therapy in stroke rehabilitation: a review</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1997</YR>
<VL>90</VL>
<PG>33-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moreland-1998" NAME="Moreland 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moreland JD, Thompson MA, Fuoco AR</AU>
<TI>Electromyographic biofeedback to improve lower extremity function after stroke: a meta-analysis</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1998</YR>
<VL>79</VL>
<PG>134-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RCPstroke-2004" NAME="RCPstroke 2004" TYPE="OTHER">
<TI>National Clinical Guidelines for Stroke: Update 2004</TI>
<SO>http://www.rcplondon.ac.uk/pubs/books/stroke/StrokeUpdate2004.pdf</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schleenbaker-1993" NAME="Schleenbaker 1993" TYPE="JOURNAL_ARTICLE">
<AU>Schleenbaker RE, Mainous AG</AU>
<TI>Electromyographic biofeedback for neuromuscular reeducation in the hemiplegic stroke patient: a meta-analysis</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1993</YR>
<VL>74</VL>
<PG>1301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warlow-1998" NAME="Warlow 1998" TYPE="JOURNAL_ARTICLE">
<AU>Warlow CP</AU>
<TI>Epidemiology of stroke</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352 (Suppl III)</VL>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolfe-2000" NAME="Wolfe 2000" NOTES="&lt;p&gt;Epidemiology of stroke&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe CDA</AU>
<TI>The impact of stroke</TI>
<SO>British Medical Bulletin</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>2</NO>
<PG>275-86</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Armagan-2003">
<CHAR_METHODS>
<P>RCT of 4-week duration<BR/>Randomisation by numbered envelopes<BR/>Assessments by a blinded evaluator</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>27 participants (14 intervention, 13 control)<BR/>Mean age 57 years (range 39 to 77 years)<BR/>Mean time from stroke of 4.6 months (range 3 to 6 months)<BR/>59% male<BR/>Exclusions included significant cognitive impairment or limb spasticity, and previous physiotherapy or EMG feedback therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exercise program plus EMG-BFB or exercise plus placebo EMG-BFB<BR/>20-minute sessions 5 times a week for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Brunstrom's Stages of Hand Recovery, a scale for judging drinking from a glass, active range of motion at wrist and EMG surface potentials</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Basmajian-1987">
<CHAR_METHODS>
<P>RCT of 5-week duration plus 9 month follow up<BR/>Randomisation method 'balanced' after every 4 patients and across strata<BR/>Assessments by a blinded evaluator</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>29 participants (13 intervention, 16 control)<BR/>Mean age 62 years<BR/>Mean time from stroke 16 weeks<BR/>66% male</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physiotherapy alone vs physiotherapy plus EMG-BFB<BR/>45-minute sessions 3 times a week for 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Upper Extremity Function Test<BR/>Finger Oscillation Test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Binder-1981">
<CHAR_METHODS>
<P>RCT of 4-week duration<BR/>Randomisation method that maintained equivalent numbers between groups<BR/>Assessments performed by a blinded evaluator</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 participants (5 in each group)<BR/>Mean age unknown, at least 16 months from stroke event<BR/>% male unknown<BR/>Patients with residual lower limb weakness but able to walk short distances</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physiotherapy alone vs physiotherapy plus EMG-BFB<BR/>30 to 40-minute treatment sessions 3 times a week for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Active range of ankle movement<BR/>Time to walk 50 metres on both smooth and carpeted surfaces</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bradley-1998">
<CHAR_METHODS>
<P>RCT of 6-week duration plus further 12 week follow up<BR/>Randomisation method not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Data available for a total of 21 participants (12 intervention, 9 control)<BR/>Mean age 70 years<BR/>Mean time from stroke 36 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physiotherapy plus EMG-BFB vs physiotherapy alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time taken and number of steps to do a 10 metre walk (but only 14 subjects able to perform)<BR/>Rivermead mobility index<BR/>Range of movement at ankle<BR/>Nottingham extended ADL index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Burnside-1982">
<CHAR_METHODS>
<P>RCT of 6-week duration with 12-week follow up<BR/>Groups matched on age, duration and initial strength<BR/>Assessments by a blinded evaluator</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>22 participants (11 in each group)<BR/>Mean age 70 years<BR/>Mean time from stroke of 4.8 years<BR/>46% male<BR/>Patients at least 3 months from a stroke event and with residual lower limb weakness but able to walk short distances</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exercise program plus EMG-BFB or exercise plus placebo EMG-BFB<BR/>15-minute sessions twice a week for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle strength of tibialis anterior (MRC scale 0 to 5)<BR/>Active range of movement at ankle<BR/>Basmajian's rating scale for gait</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cozean-1988">
<CHAR_METHODS>
<P>RCT of 6-week duration<BR/>Randomisation method not stated<BR/>Assessments by a blinded evaluator<BR/>1 drop out from each group<BR/>Comparison also made to functional electrical stimulation (data not included in this review)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 participants (8 in each group)<BR/>Mean age 57 years<BR/>Mean time from stroke not stated<BR/>63 % male<BR/>Sufficient cognitive capacity to participate and able to mobilise with the assistance of one therapist</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physiotherapy alone vs physiotherapy plus EMG-BFB<BR/>30-minute sessions 3 times a week for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Stride length<BR/>Gait cycle time<BR/>Angles of knee and ankle during walking</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Crow-1989">
<CHAR_METHODS>
<P>RCT of 6-week duration plus 12-week follow up<BR/>Randomisation by a method to balance stratified groups<BR/>3 patients died during the trial, their allocation groups are not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 participants (20 in each group)<BR/>Mean age 68 years<BR/>Between 2 and 8 weeks poststroke<BR/>63% male<BR/>Residual arm weakness but at least some movement, reasonable cognitive ability</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physiotherapy alone vs physiotherapy plus EMG-BFB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Brunnstrom-Fugl Meyer test<BR/>Action Research Arm test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Inglis-1984">
<CHAR_METHODS>
<P>Cross-over design; data extracted for first intervention period only<BR/>Randomisation method not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 participants (15 in each group)<BR/>Mean age 61 years<BR/>Mean time of 19 months post-stroke<BR/>66% male</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>20 sessions of EMG-BFB plus physiotherapy or physiotherapy alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Brunnstrom Stages of recovery (raw data not available for active range of motion at the shoulder or Oxford Scale muscle strength scores)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Intiso-1994">
<CHAR_METHODS>
<P>Unclear if the study was truly randomised; randomisation of the patients is not mentioned in the published article and so caution should used when interpreting this study<BR/>2-month duration</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 participants (8 in each group) but 2 from the control group did not complete the rehabilitation program<BR/>Mean age 57 years<BR/>Mean time from stroke 9.8 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EMG plus physical therapy vs physical therapy alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Barthel, Canadian, Adams, Basmajian and Ashworth scales used<BR/>Stride length and gait speed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lee-1985">
<CHAR_METHODS>
<P>RCT of 16-week duration<BR/>Randomisation method unknown</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 participants (13 in each group)<BR/>Mean age 52 years<BR/>Mean time from stroke 5.1 months<BR/>81% male</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physiotherapy alone vs physiotherapy plus EMG-BFB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Active range of motion at wrist and ankle<BR/>EMG potentials</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mroczek-1978">
<CHAR_METHODS>
<P>RCT of 4-week duration<BR/>Cross-over design; data extracted for first intervention period only<BR/>Randomisation method not stated<BR/>2 patients with a left-sided hemiplegia were specifically allocated one to each group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>9 participants (5 intervention, 4 control)<BR/>Age range 50 to 75 years<BR/>Between 1 and 10 years post-stroke</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EMG plus physical therapy vs physical therapy alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Active range of motion at wrist<BR/>EMG potentials</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mulder-1986">
<CHAR_METHODS>
<P>RCT of 5-week duration<BR/>Randomisation method not stated<BR/>Assessments by a blinded evaluator</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 participants (6 in each group)<BR/>Age range 34 to 68 years<BR/>67% male<BR/>Patients at least 6 months from a stroke event with residual lower limb weakness but able to walk short distances, adequate mental function</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physiotherapy alone vs physiotherapy plus EMG-BFB<BR/>40-minute sessions 3 times a week for 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Active range of movement at ankle joint (but raw data not provided for this outcome measure)<BR/>EMG potentials<BR/>Analysis of gait</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smith-1979">
<CHAR_METHODS>
<P>RCT of 6-week duration<BR/>Randomisation method not stated<BR/>Assessments by a blinded evaluator</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>11 participants (6 intervention, 5 control)<BR/>Mean age 52 years<BR/>Mean time from stroke 18 months (1 with subarachnoid haemorrhage)<BR/>46% male<BR/>Patients at least 6 months from a stroke event with residual lower limb weakness but able to walk short distances, adequate mental function</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exercise program plus EMG-BFB or exercise alone<BR/>1-hour sessions twice a week for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Grading score of gait from video analysis<BR/>Patient questionnaires on perceived sensory and motor function of affected limb</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL: activities of daily living<BR/>EMG: electromyograph<BR/>EMG-BFB: electromyographic biofeedback<BR/>RCT: randomised controlled trial<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Basmajian-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data published in the study to perform analyses<BR/>Unable to contact the authors for further data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data to extract results from the first stage of the trial (cross-over design)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ince-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only ever published as an abstract<BR/>Unable to contact the authors for further data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ince-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to obtain copies of articles from the journal 'Medical Psychotherapy' from any library in the UK</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mandel-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data published to perform analyses<BR/>Unable to obtain further information from authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olney-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only ever published as an abstract<BR/>Insufficient data available and unclear if EMG-BFB was used in isolation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prevo-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data published to allow analysis<BR/>Unable to contact the authors for further information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shahani-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only published as an abstract<BR/>Unable to contact the authors for further data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taskiran-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Difficulties with translation from Turkish<BR/>Unclear what outcome measures were used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolf-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data published to perform analyses<BR/>Unable to contact authors for further information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>EMG-BFB: electromyographic biofeedback</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Armagan-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Basmajian-1987">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Binder-1981">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bradley-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Burnside-1982">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cozean-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Crow-1989">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Inglis-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Intiso-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Mroczek-1978">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mulder-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Smith-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Electromyographic biofeedback plus physical therapy versus physical therapy alone</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.6951122791003177" CI_START="0.484887720899682" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0899999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="4.1474433310048197E-4" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" UNITS="" WEIGHT="99.99999999999999" Z="3.5305195695665015">
<NAME>Change in motor strength (MRC scale)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.695112279100318" CI_START="0.4848877208996819" EFFECT_SIZE="1.0899999999999999" ESTIMABLE="YES" MEAN_1="1.18" MEAN_2="0.09" ORDER="5908" SD_1="0.87" SD_2="0.54" SE="0.30873642774732923" STUDY_ID="STD-Burnside-1982" TOTAL_1="11" TOTAL_2="11" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.838622390502582" CI_END="0.5004456113091658" CI_START="-0.17298623122627665" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.16372969004144455" ESTIMABLE="YES" I2="10.698594073349833" I2_Q="57.57226359940913" ID="CMP-001.02" NO="2" P_CHI2="0.347039110159712" P_Q="0.06967371271775513" P_Z="0.3405689823382253" Q="7.070846230576233" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="73" TOTAL_2="69" UNITS="" WEIGHT="400.0" Z="0.9530416455299964">
<NAME>Change in range of motion</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7677761599263488" CI_END="0.4621322876341533" CI_START="-0.364600429105527" DF="4.0" EFFECT_SIZE="0.048765929264313154" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.9427151740963814" P_Z="0.8171422101910716" STUDIES="5" TAU2="0.0" TOTAL_1="47" TOTAL_2="44" WEIGHT="100.00000000000001" Z="0.23122216671818854">
<NAME>Ankle joint</NAME>
<CONT_DATA CI_END="1.0146364585396836" CI_START="-1.4782449068963632" EFFECT_SIZE="-0.2318042241783397" ESTIMABLE="YES" MEAN_1="15.38" MEAN_2="17.44" ORDER="1" SD_1="6.58" SD_2="9.25" SE="0.6359508095810884" STUDY_ID="STD-Binder-1981" TOTAL_1="5" TOTAL_2="5" WEIGHT="10.99833709849325"/>
<CONT_DATA CI_END="0.9944092273973415" CI_START="-0.6801918316309696" EFFECT_SIZE="0.1571086978831859" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="5.18" ORDER="3" SD_1="12.3" SD_2="8.4" SE="0.4272019976482605" STUDY_ID="STD-Burnside-1982" TOTAL_1="11" TOTAL_2="11" WEIGHT="24.372917925545536"/>
<CONT_DATA CI_END="0.7952317785987617" CI_START="-0.7423695884208703" EFFECT_SIZE="0.026431095088945672" ESTIMABLE="YES" MEAN_1="12.31" MEAN_2="11.92" ORDER="5" SD_1="9.53" SD_2="17.82" SE="0.39225245441958" STUDY_ID="STD-Lee-1985" TOTAL_1="13" TOTAL_2="13" WEIGHT="28.909643500537264"/>
<CONT_DATA CI_END="1.3001686739456486" CI_START="-0.6477294266882274" EFFECT_SIZE="0.32621962362871065" ESTIMABLE="YES" MEAN_1="14.9" MEAN_2="12.43" ORDER="5910" SD_1="8.48" SD_2="4.61" SE="0.4969219118306886" STUDY_ID="STD-Bradley-1998" TOTAL_1="10" TOTAL_2="7" WEIGHT="18.013486600973813"/>
<CONT_DATA CI_END="0.8104794223176093" CI_START="-1.1542810752101713" EFFECT_SIZE="-0.171900826446281" ESTIMABLE="YES" MEAN_1="107.0" MEAN_2="109.0" ORDER="5912" SD_1="11.0" SD_2="11.0" SE="0.5012236227363259" STUDY_ID="STD-Cozean-1988" TOTAL_1="8" TOTAL_2="8" WEIGHT="17.70561487445014"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6967363205116512" CI_START="0.07295769684922604" DF="0.0" EFFECT_SIZE="0.8848470086804386" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.032672115962597836" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="2.136089542711218">
<NAME>Shoulder joint</NAME>
<CONT_DATA CI_END="1.6967363205116512" CI_START="0.07295769684922604" EFFECT_SIZE="0.8848470086804386" ESTIMABLE="YES" MEAN_1="39.23" MEAN_2="14.62" ORDER="5914" SD_1="31.06" SD_2="22.05" SE="0.4142368524295813" STUDY_ID="STD-Lee-1985" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.349181145592633" CI_START="-1.6816372073278145" DF="0.0" EFFECT_SIZE="-0.6662280308675907" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="1.0" P_Z="0.19845449169469312" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.285967249718536">
<NAME>Knee joint</NAME>
<CONT_DATA CI_END="0.349181145592633" CI_START="-1.6816372073278145" EFFECT_SIZE="-0.6662280308675907" ESTIMABLE="YES" MEAN_1="143.0" MEAN_2="149.0" ORDER="5915" SD_1="8.0" SD_2="9.0" SE="0.5180754261147866" STUDY_ID="STD-Cozean-1988" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.4041491625327014" CI_START="-0.48023342155980786" DF="0.0" EFFECT_SIZE="0.9619578704864469" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" NO="4" P_CHI2="1.0" P_Z="0.19110469927107812" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.0" Z="1.3073181007237784">
<NAME>Wrist joint</NAME>
<CONT_DATA CI_END="2.4041491625327014" CI_START="-0.48023342155980786" EFFECT_SIZE="0.9619578704864469" ESTIMABLE="YES" MEAN_1="14.4" MEAN_2="6.7" ORDER="5916" SD_1="8.94" SD_2="3.4" SE="0.7358254046615528" STUDY_ID="STD-Mroczek-1978" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3268073809806371" CI_END="0.1877960656735536" CI_START="-0.08363060619958723" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.05208272973698319" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.9549103558354689" P_Q="0.6894940318059051" P_Z="0.45194540633025904" Q="0.15963387109626637" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="27" UNITS="" WEIGHT="200.0" Z="0.7521757076897035">
<NAME>Change in stride length</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.08641641209257295" CI_END="2.250022311610969" CI_START="-3.269700793638125" DF="1.0" EFFECT_SIZE="-0.509839241013578" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.7687833737886252" P_Z="0.7172987804357265" STUDIES="2" TAU2="0.0" TOTAL_1="15" TOTAL_2="11" WEIGHT="100.00000000000001" Z="0.36207126018389457">
<NAME>Change in number of steps taken to walk 6 metres or 10 metres</NAME>
<CONT_DATA CI_END="8.208245027272062" CI_START="-7.0882450272720625" EFFECT_SIZE="0.5599999999999996" ESTIMABLE="YES" MEAN_1="-7.44" MEAN_2="-8.0" ORDER="5917" SD_1="7.78" SD_2="6.52" SE="3.9022375347712726" STUDY_ID="STD-Bradley-1998" TOTAL_1="9" TOTAL_2="5" WEIGHT="13.021199917595297"/>
<CONT_DATA CI_END="2.2892427369652673" CI_START="-3.629242736965267" EFFECT_SIZE="-0.67" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="0.17" ORDER="5918" SD_1="1.97" SD_2="3.13" SE="1.5098454667062233" STUDY_ID="STD-Mulder-1986" TOTAL_1="6" TOTAL_2="6" WEIGHT="86.97880008240472"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0807570977917978" CI_END="0.18932251183782897" CI_START="-0.08243292193246624" DF="1.0" EFFECT_SIZE="0.05344479495268137" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.7762740351718154" P_Z="0.44075861700866814" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.7709128153582736">
<NAME>Stride length at end of intervention (metres)</NAME>
<CONT_DATA CI_END="0.24748228736888597" CI_START="-0.10748228736888607" EFFECT_SIZE="0.06999999999999995" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.54" ORDER="5919" SD_1="0.2" SD_2="0.16" SE="0.09055385138137417" STUDY_ID="STD-Cozean-1988" TOTAL_1="8" TOTAL_2="8" WEIGHT="58.61198738170347"/>
<CONT_DATA CI_END="0.24120828713691742" CI_START="-0.18120828713691736" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.5" ORDER="5920" SD_1="0.2" SD_2="0.23" SE="0.10776131031126153" STUDY_ID="STD-Intiso-1994" TOTAL_1="8" TOTAL_2="8" WEIGHT="41.388012618296536"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.5374985808610893" CI_END="0.3747707329190633" CI_START="-0.603800760791338" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.11451501393613739" ESTIMABLE="YES" I2="0.0" I2_Q="11.856685281974434" ID="CMP-001.04" NO="4" P_CHI2="0.472199609196873" P_Q="0.32157807905362323" P_Z="0.6464350382384103" Q="2.269031980925712" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="32" UNITS="" WEIGHT="300.0" Z="0.4587202967724176">
<NAME>Change in gait speed</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2684665999353775" CI_END="0.8018951603346266" CI_START="-0.5478179930409807" DF="2.0" EFFECT_SIZE="0.12703858364682294" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="0.5303419715699569" P_Z="0.712161996153248" STUDIES="3" TAU2="0.0" TOTAL_1="20" TOTAL_2="16" WEIGHT="100.0" Z="0.36895402252253395">
<NAME>Change in time taken to walk a specified distance</NAME>
<CONT_DATA CI_END="2.0247393029839964" CI_START="-0.5837912373113132" EFFECT_SIZE="0.7204740328363415" ESTIMABLE="YES" MEAN_1="18.8" MEAN_2="-10.9" ORDER="5921" SD_1="49.61" SD_2="17.65" SE="0.6654536922288025" STUDY_ID="STD-Binder-1981" TOTAL_1="5" TOTAL_2="5" WEIGHT="26.772634496648674"/>
<CONT_DATA CI_END="0.8422346297646846" CI_START="-1.3556768610552605" EFFECT_SIZE="-0.25672111564528804" ESTIMABLE="YES" MEAN_1="-24.44" MEAN_2="-18.6" ORDER="5922" SD_1="22.14" SD_2="19.5" SE="0.5607020098728319" STUDY_ID="STD-Bradley-1998" TOTAL_1="9" TOTAL_2="5" WEIGHT="37.71052350392325"/>
<CONT_DATA CI_END="1.2195542666974937" CI_START="-1.0452168025291784" EFFECT_SIZE="0.08716873208415758" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="-3.15" ORDER="5923" SD_1="5.13" SD_2="13.27" SE="0.5777583381865425" STUDY_ID="STD-Mulder-1986" TOTAL_1="6" TOTAL_2="6" WEIGHT="35.51684199942807"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2258357024217018" CI_START="-1.8368877197315054" DF="0.0" EFFECT_SIZE="-0.8055260086549018" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="0.12582039771727235" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.5307936571795453">
<NAME>Gait cycle time at end of intervention</NAME>
<CONT_DATA CI_END="0.2258357024217018" CI_START="-1.8368877197315054" EFFECT_SIZE="-0.8055260086549018" ESTIMABLE="YES" MEAN_1="2.29" MEAN_2="3.05" ORDER="5924" SD_1="0.83" SD_2="0.95" SE="0.52621462394812" STUDY_ID="STD-Cozean-1988" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9799819922700271" CI_START="-0.9799819922700271" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.0">
<NAME>Walking velocity (m/s) at end of intervention</NAME>
<CONT_DATA CI_END="0.9799819922700271" CI_START="-0.9799819922700271" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.16" ORDER="5925" SD_1="0.08" SD_2="0.09" SE="0.5" STUDY_ID="STD-Intiso-1994" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.963840907343082" CI_END="0.5571725322702452" CI_START="-0.06881913609994644" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.24417669808514936" ESTIMABLE="YES" I2="28.200542394245293" I2_Q="42.55575084095517" ID="CMP-001.05" NO="5" P_CHI2="0.2233435030612302" P_Q="0.13784201828976572" P_Z="0.1262589760634068" Q="6.963273188453163" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="81" UNITS="" WEIGHT="500.0" Z="1.5290220566571107">
<NAME>Changes in functional ability</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.677188899183873E-4" CI_END="1.228995926732055" CI_START="0.15479679552077996" DF="1.0" EFFECT_SIZE="0.6918963611264175" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="0.9809907215073503" P_Z="0.011575006713171262" STUDIES="2" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="2.5248427585543807">
<NAME>Change in Brunnstrom Stages of Recovery score</NAME>
<CONT_DATA CI_END="1.4801789199680442" CI_START="-0.08258765931369294" EFFECT_SIZE="0.6987956303271756" ESTIMABLE="YES" MEAN_1="0.86" MEAN_2="0.54" ORDER="5926" SD_1="0.36" SD_2="0.52" SE="0.3986722693908257" STUDY_ID="STD-Armagan-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="47.2477752312476"/>
<CONT_DATA CI_END="1.4252105837610158" CI_START="-0.053776586543427984" EFFECT_SIZE="0.6857169986087939" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.2" ORDER="5927" SD_1="0.52" SD_2="0.41" SE="0.37729957845412104" STUDY_ID="STD-Inglis-1984" TOTAL_1="15" TOTAL_2="15" WEIGHT="52.7522247687524"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.065947528221902" CI_START="-0.19001864814399744" DF="0.0" EFFECT_SIZE="0.43796444003895224" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="1.0" P_Z="0.17165443273081804" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.3669070794077234">
<NAME>Change in Brunnstrom-Fugl Meyer test score</NAME>
<CONT_DATA CI_END="1.065947528221902" CI_START="-0.19001864814399744" EFFECT_SIZE="0.43796444003895224" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="6.9" ORDER="5928" SD_1="12.53" SD_2="10.67" SE="0.3204054223120425" STUDY_ID="STD-Crow-1989" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.5023054320745725E-33" CI_END="0.5620164022871874" CI_START="-0.9047331961754359" DF="0.0" EFFECT_SIZE="-0.1713583969441243" ESTIMABLE="YES" I2="100.0" ID="CMP-001.05.03" NO="3" P_CHI2="0.0" P_Z="0.6469812164192934" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="16" WEIGHT="100.0" Z="0.4579599500978635">
<NAME>Upper Extremity Function test score at end of intervention</NAME>
<CONT_DATA CI_END="0.5620164022871874" CI_START="-0.9047331961754359" EFFECT_SIZE="-0.17135839694412427" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="52.37" ORDER="5929" SD_1="27.04" SD_2="32.94" SE="0.3741776915372315" STUDY_ID="STD-Basmajian-1987" TOTAL_1="13" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7705515394914682" CI_START="-1.1967797685589747" DF="0.0" EFFECT_SIZE="-0.21311411453375334" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.04" NO="4" P_CHI2="1.0" P_Z="0.671104907235053" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.42463207633006456">
<NAME>Barthel index score at end of intervention</NAME>
<CONT_DATA CI_END="0.7705515394914682" CI_START="-1.1967797685589747" EFFECT_SIZE="-0.21311411453375334" ESTIMABLE="YES" MEAN_1="78.7" MEAN_2="82.5" ORDER="5930" SD_1="18.2" SD_2="15.4" SE="0.5018794537982588" STUDY_ID="STD-Intiso-1994" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5089006285689136" CI_START="-1.2367949767185817" DF="0.0" EFFECT_SIZE="-0.3639471740748341" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.05" NO="5" P_CHI2="1.0" P_Z="0.41379311823555054" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="100.0" Z="0.817236809557447">
<NAME>Change in Rivermead Mobility Index score</NAME>
<CONT_DATA CI_END="0.5089006285689136" CI_START="-1.2367949767185817" EFFECT_SIZE="-0.3639471740748341" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="3.78" ORDER="5931" SD_1="3.37" SD_2="2.86" SE="0.4453386947559546" STUDY_ID="STD-Bradley-1998" TOTAL_1="12" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in gait quality score</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7827534234429663" CI_START="0.01179675905127886" EFFECT_SIZE="0.8972750912471226" ESTIMABLE="YES" MEAN_1="0.72" MEAN_2="0.09" ORDER="5932" SD_1="0.65" SD_2="0.7" SE="0.4517829609015185" STUDY_ID="STD-Burnside-1982" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.6807997572106534" CI_START="-0.7427388313709933" EFFECT_SIZE="0.46903046291983014" ESTIMABLE="YES" MEAN_1="8.43" MEAN_2="5.68" ORDER="5933" SD_1="5.77" SD_2="4.8" SE="0.6182610006352692" STUDY_ID="STD-Smith-1979" TOTAL_1="6" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2023385917476332" CI_END="3.9567547196990938" CI_START="-3.266380861867208" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3451869289159429" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.7524435404209366" P_Q="0.7371028568749247" P_Z="0.8514021298004251" Q="0.11268940904089231" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="36" UNITS="" WEIGHT="99.99999999999999" Z="0.18732971047527489">
<NAME>Sham EMG-BFB versus no placebo: range of motion at ankle joint</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.522002041741269" CI_START="-7.0820020417412675" DF="0.0" EFFECT_SIZE="1.7200000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.7017221849564692" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="16.835600531278526" Z="0.38299673613140794">
<NAME>Sham therapy</NAME>
<CONT_DATA CI_END="10.522002041741269" CI_START="-7.0820020417412675" EFFECT_SIZE="1.7200000000000006" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="5.18" ORDER="3" SD_1="12.3" SD_2="8.4" SE="4.490899889574674" STUDY_ID="STD-Burnside-1982" TOTAL_1="11" TOTAL_2="11" WEIGHT="16.835600531278526"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.089649182706741" CI_END="4.027163578737608" CI_START="-3.8934174081808925" DF="2.0" EFFECT_SIZE="0.06687308527835761" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="0.5799436203358055" P_Z="0.9735982209108561" STUDIES="3" TAU2="0.0" TOTAL_1="28" TOTAL_2="25" WEIGHT="83.16439946872146" Z="0.03309576378225985">
<NAME>No placebo</NAME>
<CONT_DATA CI_END="3.7116796317986065" CI_START="-7.8316796317986075" EFFECT_SIZE="-2.0600000000000005" ESTIMABLE="YES" MEAN_1="15.38" MEAN_2="17.44" ORDER="1" SD_1="6.58" SD_2="0.25" SE="2.944788617201581" STUDY_ID="STD-Binder-1981" TOTAL_1="5" TOTAL_2="5" WEIGHT="39.15498923324898"/>
<CONT_DATA CI_END="11.375127062116475" CI_START="-10.595127062116473" EFFECT_SIZE="0.39000000000000057" ESTIMABLE="YES" MEAN_1="12.31" MEAN_2="11.92" ORDER="5" SD_1="9.53" SD_2="17.82" SE="5.604759653119014" STUDY_ID="STD-Lee-1985" TOTAL_1="13" TOTAL_2="13" WEIGHT="10.80889686698506"/>
<CONT_DATA CI_END="8.737918944560054" CI_START="-3.7979189445600525" EFFECT_SIZE="2.4700000000000006" ESTIMABLE="YES" MEAN_1="14.9" MEAN_2="12.43" ORDER="5936" SD_1="8.48" SD_2="4.61" SE="3.197976592427513" STUDY_ID="STD-Bradley-1998" TOTAL_1="10" TOTAL_2="7" WEIGHT="33.20051336848742"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2023385917476332" CI_END="3.9567547196990938" CI_START="-3.266380861867208" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.34518692891594294" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.7524435404209366" P_Q="0.43743511906538746" P_Z="0.851402129800425" Q="0.6030019073431038" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="0.18732971047527494">
<NAME>Time from stroke and change in range of movement at ankle</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.10389913528156038" CI_END="7.403204399069637" CI_START="-3.484917953649722" DF="1.0" EFFECT_SIZE="1.959143222709957" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="0.7471997935504924" P_Z="0.4806059872412758" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="20" WEIGHT="44.00941023547248" Z="0.7053282526914716">
<NAME>Less than 6 months</NAME>
<CONT_DATA CI_END="11.375127062116475" CI_START="-10.595127062116473" EFFECT_SIZE="0.39000000000000057" ESTIMABLE="YES" MEAN_1="12.31" MEAN_2="11.92" ORDER="5" SD_1="9.53" SD_2="17.82" SE="5.604759653119014" STUDY_ID="STD-Lee-1985" TOTAL_1="13" TOTAL_2="13" WEIGHT="10.80889686698506"/>
<CONT_DATA CI_END="8.737918944560054" CI_START="-3.7979189445600525" EFFECT_SIZE="2.4700000000000006" ESTIMABLE="YES" MEAN_1="14.9" MEAN_2="12.43" ORDER="5938" SD_1="8.48" SD_2="4.61" SE="3.197976592427513" STUDY_ID="STD-Bradley-1998" TOTAL_1="10" TOTAL_2="7" WEIGHT="33.20051336848742"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4954375491229691" CI_END="3.903160039026825" CI_START="-5.749971980966731" DF="1.0" EFFECT_SIZE="-0.923405970969953" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="0.48151176245241323" P_Z="0.7076789283049508" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="55.99058976452751" Z="0.3749751774785226">
<NAME>More than 6 months</NAME>
<CONT_DATA CI_END="3.7116796317986065" CI_START="-7.8316796317986075" EFFECT_SIZE="-2.0600000000000005" ESTIMABLE="YES" MEAN_1="15.38" MEAN_2="17.44" ORDER="1" SD_1="6.58" SD_2="0.25" SE="2.944788617201581" STUDY_ID="STD-Binder-1981" TOTAL_1="5" TOTAL_2="5" WEIGHT="39.15498923324898"/>
<CONT_DATA CI_END="10.522002041741269" CI_START="-7.0820020417412675" EFFECT_SIZE="1.7200000000000006" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="5.18" ORDER="3" SD_1="12.3" SD_2="8.4" SE="4.490899889574674" STUDY_ID="STD-Burnside-1982" TOTAL_1="11" TOTAL_2="11" WEIGHT="16.835600531278526"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-08-19 12:30:00 +0100" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2008-08-19 12:30:00 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-08-19 12:29:44 +0100" MODIFIED_BY="Hazel Fraser">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-19 12:30:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>The following strategy was used for MEDLINE and modified for the other databases.</P>
<P>MEDLINE (Ovid)<BR/>1. electromyography/<BR/>2. "biofeedback (psychology)"/ or feedback/ or feedback, psychological/<BR/>3. (electromyograph$ or electromyogram$ or EMG$).tw.<BR/>4. (biofeedback or feedback).tw.<BR/>5. 1 or 2 or 3 or 4<BR/>6. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp cerebrovascular accident/ or exp hypoxia-ischemia, brain/ or exp intracranial artery diseases/ or exp "intracranial embolism and thrombosis"/ or exp intracranial hemorrhages/<BR/>7. (stroke or poststroke or cerebrovasc$ or cerebral vasc$ or cva$).tw.<BR/>8. ((cerebral or cerebellar or brain$ or vertebrobasilar) adj5 (infarct$ or isch?emi$ or thrombo$ or emboli$ or apoplexy)).tw.<BR/>9. ((cerebral or brain$ or subarachnoid) adj5 (haemorrhage or hemorrhage or haematoma or hematoma or bleed$)).tw.<BR/>10. hemiplegia/ or (hemipleg$ or hemipar$).tw.<BR/>11. 6 or 7 or 8 or 9 or 10<BR/>12. 5 and 11<BR/>13. limit 12 to human<BR/>14. cerebrovascular disorders/rh or exp basal ganglia cerebrovascular disease/rh or exp brain ischemia/rh or exp carotid artery diseases/rh or exp cerebrovascular accident/rh or exp hypoxia-ischemia, brain/rh or exp intracranial arterial diseases/rh or exp "intracranial embolism and thrombosis"/rh or exp intracranial hemorrhages/rh<BR/>15. hemiplegia/ or paresis/rh<BR/>16. 14 or 15<BR/>17. 5 and 16<BR/>18. exp rehabilitation/<BR/>19. motor activity/ or movement/ or range of motion, articular/<BR/>20. recovery of function/ or disability evaluation/ or muscle weakness/<BR/>21. gait/ or locomotion/ or walking/<BR/>22. (recovery or motor function or gait or ambulation or muscle weakness or muscle power or movement or mobility).tw.<BR/>23. 18 or 19 or 20 or 21 or 22<BR/>24. 13 and 23<BR/>25. 17 or 24</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>